Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Danicopan

FDA-approved product (tablet, oral), marketed as Voydeya.

Registered studies
30
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Danicopan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acquired paroxysmal nocturnal hemoglobinuria
  • Hemoglobinuria, Paroxysmal
  • Hemolysis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Complement inhibitors
FDA pharmacologic class
Complement Factor D Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA68.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Danicopan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Danicopan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

    NCT03459443 · start 2018-06-20

    Registered record
    Registry ID
    NCT03459443
    Conditions
    C3 Glomerulonephritis; C3 Glomerulopathy; Immune Complex Membranoproliferative Glomerulonephritis; IC-MPGN; Dense Deposit Disease
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-06-20
    Completion
    2021-03-29
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionC3 Glomerulonephritis; C3 Glomerulopathy; Immune Complex Membranoproliferative Glomerulonephritis; IC-MPGN +1 more
    InterventionDanicopan
    PhasePhase 2
    Registry statusTerminated

  • A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

    NCT03369236 · start 2018-06-12

    Registered record
    Registry ID
    NCT03369236
    Conditions
    C3 Glomerulopathy; C3 Glomerulonephritis; Dense Deposit Disease
    Interventions
    Danicopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-12
    Completion
    2020-12-18
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionC3 Glomerulopathy; C3 Glomerulonephritis; Dense Deposit Disease
    InterventionDanicopan; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

    NCT03472885 · start 2018-05-08

    Registered record
    Registry ID
    NCT03472885
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Interventions
    Danicopan; Eculizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-08
    Completion
    2023-01-05
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria (PNH)
    InterventionDanicopan; Eculizumab
    PhasePhase 2
    Registry statusCompleted

  • Study of Danicopan in Participants With Hepatic Impairment

    NCT03555539 · start 2018-05-01

    Registered record
    Registry ID
    NCT03555539
    Conditions
    Hepatic Impairment
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-01
    Completion
    2018-09-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionDanicopan
    PhasePhase 1
    Registry statusCompleted

  • Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

    NCT04935294 · start 2018-01-24

    Registered record
    Registry ID
    NCT04935294
    Conditions
    Healthy; Renal Dysfunction
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-01-24
    Completion
    2018-05-29
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Renal Dysfunction
    InterventionDanicopan
    PhasePhase 1
    Registry statusCompleted

  • A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

    NCT03384186 · start 2017-12-01

    Registered record
    Registry ID
    NCT03384186
    Conditions
    Healthy
    Interventions
    Danicopan Modified Release Prototype 1; Danicopan Modified Release Prototype 2; Danicopan Modified Release Prototype 3
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-01
    Completion
    2018-03-21
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan Modified Release Prototype 1; Danicopan Modified Release Prototype 2; Danicopan Modified Release Prototype 3
    PhasePhase 1
    Registry statusCompleted

  • Study of Radiolabeled Danicopan in Healthy Male Participants

    NCT04889391 · start 2017-09-14

    Registered record
    Registry ID
    NCT04889391
    Conditions
    Healthy
    Interventions
    [14C]-Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-14
    Completion
    2017-10-15
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention[14C]-Danicopan
    PhasePhase 1
    Registry statusCompleted

  • A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

    NCT03124368 · start 2017-08-09

    Registered record
    Registry ID
    NCT03124368
    Conditions
    C3 Glomerulonephritis; Dense Deposit Disease; C3 Glomerulopathy; Immune Complex Mediated Membranoproliferative Glomerulonephritis; Membranoproliferative Glomerulonephritis Types I, II, and III
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-08-09
    Completion
    2019-01-09
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionC3 Glomerulonephritis; Dense Deposit Disease; C3 Glomerulopathy; Immune Complex Mediated Membranoproliferative Glomerulonephritis +1 more
    InterventionDanicopan
    PhasePhase 2
    Registry statusCompleted

  • A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

    NCT03181633 · start 2017-06-22

    Registered record
    Registry ID
    NCT03181633
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria
    Interventions
    ACH-0144471
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-22
    Completion
    2022-01-04
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria
    InterventionACH-0144471
    PhasePhase 2
    Registry statusCompleted

  • A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants

    NCT03108274 · start 2017-04-18

    Registered record
    Registry ID
    NCT03108274
    Conditions
    Healthy
    Interventions
    Danicopan; Midazolam; Fexofenadine; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-18
    Completion
    2017-06-16
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Midazolam; Fexofenadine; Mycophenolate Mofetil
    PhasePhase 1
    Registry statusCompleted

  • Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

    NCT03053102 · start 2017-03-31

    Registered record
    Registry ID
    NCT03053102
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Interventions
    Danicopan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-03-31
    Completion
    2018-11-14
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria (PNH)
    InterventionDanicopan
    PhasePhase 2
    Registry statusCompleted

  • Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

    NCT04940559 · start 2016-08-02

    Registered record
    Registry ID
    NCT04940559
    Conditions
    Healthy
    Interventions
    Danicopan - Tablet; Danicopan - Softgel; Danicopan - LFC
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-08-02
    Completion
    2016-10-05
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan - Tablet; Danicopan - Softgel; Danicopan - LFC
    PhasePhase 1
    Registry statusCompleted

  • Study of Multiple Doses of Danicopan in Healthy Participants

    NCT04889690 · start 2016-05-21

    Registered record
    Registry ID
    NCT04889690
    Conditions
    Healthy
    Interventions
    Danicopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-21
    Completion
    2017-01-11
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study of a Single Dose of Danicopan in Healthy Participants

    NCT04889677 · start 2016-02-04

    Registered record
    Registry ID
    NCT04889677
    Conditions
    Healthy
    Interventions
    Danicopan; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-04
    Completion
    2016-06-21
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDanicopan; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Danicopan Early Access Program

    NCT05982938

    Registered record
    Registry ID
    NCT05982938
    Conditions
    Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis
    Interventions
    Danicopan
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParoxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis
    InterventionDanicopan
    PhaseNot recorded
    Registry statusAvailable